Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
10/2001
10/11/2001CA2404545A1 Aryl and heteroaryl sulfonates
10/11/2001CA2404413A1 Small organic molecule regulators of cell proliferation
10/11/2001CA2404386A1 Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001CA2404300A1 Medical devices suitable for gene therapy regimens
10/11/2001CA2404074A1 Human polynucleotides, polypeptides, and antibodies
10/11/2001CA2403885A1 Chemical complex comprising a pyridine carboxy derivative and an h2 histamine receptor antagonist
10/11/2001CA2403735A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase
10/11/2001CA2403600A1 Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain
10/11/2001CA2402705A1 Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
10/11/2001CA2401948A1 Cd20/ige-receptor like molecules and uses thereof
10/11/2001CA2401137A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors
10/11/2001CA2401112A1 Use of feracryl for the treatment of peptic/duodenal ulcer and/or cholera
10/10/2001EP1142906A1 A hepatitis B virus (subtype ayw) surface antigen variant
10/10/2001EP1142891A1 Use of 5-Fluoro-2'-deoxy-3'-thiacytidine for the treatment of hepatitis B
10/10/2001EP1142890A1 Aminopyrazole derivatives
10/10/2001EP1142889A1 Pyrazole derivatives as anti-inflammatory/analgesic agents
10/10/2001EP1142884A1 Oxazepine derivatives and drugs containing the same
10/10/2001EP1142868A1 Amide derivatives
10/10/2001EP1142867A2 Cell adhesion inhibitors
10/10/2001EP1142572A1 Oxetanone-containing preparations for the treatment of intestinal illnesses
10/10/2001EP1141728A1 Kidney disease detection and treatment
10/10/2001EP1141342A2 Use of plus-strand synthesis elements in retroviral vectors
10/10/2001EP1141339A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
10/10/2001EP1141334A2 Human glycosylphosphatidylinositol specific phospholipase d variants and uses thereof
10/10/2001EP1141332A1 Human cyclic nucleotide pdes
10/10/2001EP1141288A2 Lymphocytic membrane proteins
10/10/2001EP1141287A1 Pancreatic polypeptide zsig66
10/10/2001EP1141278A2 Therapeutic phosphodiesterase inhibitors
10/10/2001EP1141247A2 An animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
10/10/2001EP1141240A1 Use of cd40 engagement to alter t cell receptor usage
10/10/2001EP1141235A2 (bifidobacterium) in the treatment of inflammatory disease
10/10/2001EP1141020A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/10/2001EP1141015A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001EP1141014A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001EP1140995A2 Peptides for inhibiting hbv core proteins
10/10/2001EP1140989A1 Alpha(v) beta(6) integrin inhibitors
10/10/2001EP1140984A1 Selective inhibitors of mmp-12
10/10/2001EP1140970A1 47 human secreted proteins
10/10/2001EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140946A2 Quinoline derivatives
10/10/2001EP1140943A2 Substituted pyrroloindoles
10/10/2001EP1140939A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods
10/10/2001EP1140934A1 BENZISOXAZOLES AND PHENONES AS $g(a) 2?-ANTAGONISTS
10/10/2001EP1140924A1 Piperazine derivatives
10/10/2001EP1140923A1 Method for preparing (r)- (+) -3 1- 2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl]- 4-phenylpiperidin -4-yl -1,1- dimethylurea, its salts solvates and/or hydrates
10/10/2001EP1140915A1 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
10/10/2001EP1140914A1 Non-peptide nk1 receptors antagonists
10/10/2001EP1140912A1 Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
10/10/2001EP1140898A1 Amide and urea derivatives as 5-ht reuptake inhibitors and as 5-ht1b/1d ligands
10/10/2001EP1140895A2 Thiopyran compounds as inhibitors of mmp
10/10/2001EP1140889A2 Compounds and methods for modulation of estrogen receptors
10/10/2001EP1140849A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
10/10/2001EP1140835A1 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
10/10/2001EP1140828A1 3-azabicyclo[3.1.0]hexane derivatives as opiate receptors ligands
10/10/2001EP1140823A1 Glucagon antagonists/inverse agonists
10/10/2001EP1140792A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
10/10/2001EP1140784A2 Ion channel modulating agents
10/10/2001EP1140783A1 Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140191A1 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1140163A2 Combination of hepatitis b vaccine with antiviral agents
10/10/2001EP1140159A1 Oral vaccine against diarrhea
10/10/2001EP1140142A2 Treatment of hepatitis c virus infections with interleukin-10
10/10/2001EP1140138A2 Therapeutic applications of flint polypeptides
10/10/2001EP1140125A1 Extracts of celery seed for the prevention and treatment of pain, inflammation and gastrointestinal irritation
10/10/2001EP1140124A1 Use of unsaponifiable matters of vegetable oils for preparing a medicine
10/10/2001EP1140120A2 Human brainiac-5
10/10/2001EP1140118A1 Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
10/10/2001EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes
10/10/2001EP1140112A1 Use of etherlysophospholipids as antiinflammatory agents
10/10/2001EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
10/10/2001EP1140095A1 (2-imidazoline-2-ylamino) quinoxaline derivatives for the treatment of pain
10/10/2001EP1140091A2 Formulations comprising imiquimod or other immune response modifiers for treating mucosal consitions
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140079A1 Assays for ligands for nuclear receptors
10/10/2001EP1140077A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/10/2001EP1140072A1 Compounds and methods
10/10/2001EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
10/10/2001EP1140069A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
10/10/2001EP1140066A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use
10/10/2001EP1140065A1 Use of gamma-tocopherol and its oxidative metabolite llu-alpha in the treatment of disease
10/10/2001EP1140063A1 Method and composition for the maintenance and restitution of gut integrity
10/10/2001EP1140045A2 Homer a new target of treating psychiatric disorders
10/10/2001EP1140021A1 Improved formulation for topical non-invasive application in vivo
10/10/2001EP1140013A1 Foaming antacid suspension tablets
10/10/2001EP1139994A1 Oral hygiene product containing spherical microparticles on the basis of linear water-insoluble polyglucans
10/10/2001EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
10/10/2001EP1139793A2 Inhibitors of the bitter taste response
10/10/2001EP1139789A1 Alpha-amylase-resistant starch for producing foodstuff and medicaments
10/10/2001EP1139784A1 Food-induced antisecretory proteins in egg yolk
10/10/2001EP1139755A2 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
10/10/2001EP1139744A1 Exo-r-mecamylamine formulation and use in treatment
1 ... 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 ... 1258